These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 7927151)

  • 1. From principle to public policy: using cost-effectiveness analysis.
    Neumann PJ; Johannesson M
    Health Aff (Millwood); 1994; 13(3):206-14. PubMed ID: 7927151
    [No Abstract]   [Full Text] [Related]  

  • 2. How can Medicare keep pace with cutting-edge technology?
    Buto KA
    Health Aff (Millwood); 1994; 13(3):137-40. PubMed ID: 7927144
    [No Abstract]   [Full Text] [Related]  

  • 3. Economic evaluation and health care decision-making.
    Rutten F
    Health Policy; 1996 Jun; 36(3):215-29. PubMed ID: 10158267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apples, oranges, forests, and trees.
    Cushman R
    J Health Polit Policy Law; 1999 Aug; 24(4):763-8. PubMed ID: 10503157
    [No Abstract]   [Full Text] [Related]  

  • 5. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. The value of cost-effectiveness analyses for reimbursement decisions: perspectives from Medicare.
    Sheingold SH
    Am Heart J; 1999 May; 137(5):S81-6. PubMed ID: 10220604
    [No Abstract]   [Full Text] [Related]  

  • 6. Review of medical technology policies shows need, opportunities for changes.
    Banta D
    Hospitals; 1982 Apr; 56(7):87-90. PubMed ID: 6800914
    [No Abstract]   [Full Text] [Related]  

  • 7. Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System.
    Hasegawa M; Komoto S; Shiroiwa T; Fukuda T
    Value Health; 2020 Jan; 23(1):43-51. PubMed ID: 31952673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The which-hunt: assembling health technologies for assessment and rationing.
    Giacomini MK
    J Health Polit Policy Law; 1999 Aug; 24(4):715-58. PubMed ID: 10503155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invention to practice.
    Hillman BJ
    J Am Coll Radiol; 2006 Sep; 3(9):643-4. PubMed ID: 17412143
    [No Abstract]   [Full Text] [Related]  

  • 10. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
    Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
    Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing the Legitimacy of Tough Choices in Healthcare Reimbursement: Approach and Results of a Citizen Forum in The Netherlands.
    Bijlmakers L; Jansen M; Boer B; van Dijk W; Groenewoud S; Zwaap J; Helderman JK; van Exel J; Baltussen R
    Value Health; 2020 Jan; 23(1):32-38. PubMed ID: 31952671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The scientific basis for coverage decisions by third-party payers.
    Towery OB; Perry S
    JAMA; 1981 Jan; 245(1):59-61. PubMed ID: 6776306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technology assessment & policy determination.
    Lively L; Hugh J; Gomez B; Desai A
    Adm Radiol J; 1996 May; 15(5):50-1. PubMed ID: 10158657
    [No Abstract]   [Full Text] [Related]  

  • 14. A technology anthology. Recent writings and remarks on the state of the state-of-the-art.
    Health Syst Rev; 1997; 30(2):58, 60, 62. PubMed ID: 10165993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].
    Castillo-Laborde C; Silva-Illanes N
    Rev Med Chil; 2014 Jan; 142 Suppl 1():S33-8. PubMed ID: 24861178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harmonization of HTA--based reimbursement and regulatory approval activities: a qualitative study.
    Tsoi B; O'Reilly D; Masucci L; Drummond M; Goeree R
    J Popul Ther Clin Pharmacol; 2015; 22(1):e78-89. PubMed ID: 25715384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for outcomes research in radiology and health policy.
    McNeil BJ
    Acad Radiol; 1996 Apr; 3 Suppl 1():S19-20. PubMed ID: 8796500
    [No Abstract]   [Full Text] [Related]  

  • 18. The limited regulatory potential of medical technology assessment.
    Elhauge E
    Va Law Rev; 1996 Nov; 82(8):1525-1622. PubMed ID: 16715565
    [No Abstract]   [Full Text] [Related]  

  • 19. Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries.
    Orlewska E; Mierzejewski P
    Value Health; 2004; 7(1):1-10. PubMed ID: 14720125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicare and cost-effectiveness analysis.
    Neumann PJ; Rosen AB; Weinstein MC
    N Engl J Med; 2005 Oct; 353(14):1516-22. PubMed ID: 16207857
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.